Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV
 predominantly affects liver cells and causes the liver to become inflamed and damaged. This
 can lead to cirrhosis (scarring of the liver), liver cancer or the need for liver transplant.
 This study will evaluate how effective glecaprevir/pibrentasvir (GLE/PIB) is in participants
 with chronic HCV infection. Effectiveness will be assessed as the achievement of sustained
 virologic response.

 GLE/PIB is an approved drug for the treatment of HCV. Participants 12 years or older with
 chronic HCV infection will be enrolled. This is a prospective (conducted in future) study in
 therapy of direct-acting antiviral (DAA) treatment-experienced participants with chronic
 hepatitis C genotype 1. Around 67 participants will be enrolled at multiple sites in Russian
 Federation.

 Participants will receive oral GLE/PIB tablets as prescribed by the physician in accordance
 with local clinical practice, international guidelines and/or label. Prescription is
 independent from this study and is decided before providing opportunity to the participate in
 the study.

 There is expected to be no additional burden for participants in this trial. All study visits
 will occur during routine clinical practice and participants will be followed for 12 weeks.
Inclusion Criteria:

 -  Direct-acting antiviral treatment-experienced participants with confirmed chronic
 hepatitis C (CHC) genotype 1, receiving combination therapy with the all oral
 glecaprevir/pibrentasvir (GLE/PIB) regimens according to standard of care,
 international guidelines and in line with the current local label.

 -  Participants can enroll up to 4 weeks after starting treatment

 Exclusion Criteria:

 -  Participating or intending to participate in a concurrent interventional therapeutic
 trial.